Summary: GE Healthcare will showcase somo•v ABUS system at the 23rd Annual National Interdisciplinary Breast Center Conference (NCoBC), March 23-27, 2013.
March 25, 2013 - Dense
breast tissue not only increases the risk of breast cancer up to 4 to 6 times
but also makes cancer more difficult to detect using mammography, according to
multiple large studies. One study,
published in the New England Journal of Medicine, showed mammography sensitivity is reduced by 36% to
38% in women with dense breasts, as density masks the appearance of
tumors (Boyd, et al, NEJM 2007:356:227-36M).
The somo•v ABUS, an automated breast ultrasound system, is the only ultrasound device in the United States that has been approved by the FDA for use in breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue and no prior breast interventions. It was developed specifically for the high-volume, breast cancer screening environment. The
somo•VIEWer Advanced 3D Workstation supports expeditious reviewing and archiving of patient exams to optimize breast
ultrasound screening workflow. The somo•v ABUS system
is the only ultrasound device approved for breast cancer screening in
the United States as an adjunct to mammography for asymptomatic women with
dense breast tissue.
GE Healthcare will showcase somo•v ABUS system at the 23rd Annual
National Interdisciplinary Breast Center Conference (NCoBC), March 23-27, 2013.
the conference, GE Healthcare will conduct workshops to demonstrate typical
ABUS exam acquisition and additionally will be hosting two educational events
to introduce NCoBC attendees to ABUS.
more information: www.gehealthcare.com and www.appliedradiology.com